Previous 10 | Next 10 |
TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Health Canada has accepted ...
2023-05-14 12:00:49 ET Leqembi, the new Alzheimer's therapy developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), could add $2B - $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study. Early th...
2023-05-14 08:15:00 ET Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a ...
2023-05-12 20:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-12 10:15:00 ET Biogen (NASDAQ: BIIB) has been a polarizing stock to own over the past few years. Aduhelm's accelerated approval sent the stock soaring a few years ago, but after controversy surrounding its approval, the stock ultimately gave back much of those gains. Nowaday...
2023-05-11 05:56:21 ET The U.S. Food and Drug Administration (FDA) approved the expanded use of H. Lundbeck ( OTCPK:HLBBF ) ( OTCPK:HLUBF ) and Otsuka's ( OTCPK:OTSKY ) ( OTCPK:OTSKF ) medicine Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzh...
2023-05-10 07:05:51 ET Summary Since publishing the last article on PTC Therapeutics, the company's share price has risen 31.28%, outperforming the iShares Biotechnology ETF and the S&P 500. Overall, risdiplam is the company's third-highest-grossing medicine, with sales of CHF...
2023-05-10 02:10:00 ET Summary A punishing 2022 for Meta Platforms created a valuation opportunity - one that has paid off as it becomes the top contributor year-to-date for the Morningstar Wide Moat Focus Index. April was a subdued month - at least relative to the volatility seen...
2023-05-08 08:00:00 ET Summary Coya Therapeutics’ pipeline candidates focus on improving the quantity and functionality of regulatory T cells to alleviate the inflammatory processes associated with the progression of neurodegenerative and autoimmune diseases. Regulatory T c...
2023-05-06 01:58:52 ET Summary Like other anti-amyloid drugs, Eli Lilly's donanemab does not help APOE4 non-carriers. Donanemab does modestly slow down the progression of Alzheimer's disease during its early stages in APOE4 carriers but can cause brain bleeds and brain swelling, w...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...